Improved quality control of [177Lu]Lu-PSMA I&T

被引：0
|
作者：
Martin Kraihammer
Piotr Garnuszek
Andreas Bauman
Michael Maurin
Manuel Alejandre Lafont
Roland Haubner
Elisabeth von Guggenberg
Michael Gabriel
Clemens Decristoforo
机构：
[1] Medical University Innsbruck,Department of Nuclear Medicine
[2] Kepler University Hospital,Department of Nuclear Medicine and Endocrinology
[3] National Centre for Nuclear Research,Radioisotope Centre POLATOM
[4] University Hospital Basel,Division of Radiopharmaceutical Chemistry
来源：
EJNMMI Radiopharmacy and Chemistry | / 8卷
关键词：
PSMA; [; Lu]Lu-PSMA I&T; Zadavotide guraxetan; Radionuclide therapy; Quality control; HPLC; TLC; Validation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
    Di Iorio, Valentina
    Boschi, Stefano
    Cuni, Cristina
    Monti, Manuela
    Severi, Stefano
    Paganelli, Giovanni
    Masini, Carla
    MOLECULES, 2022, 27 (13):
  • [42] Experimental study of 68Ga/177Lu PSMA I&T: A novel PSMA inhibitor for theranostic of prostate cancer
    Zhang, Lulu
    Zhang, Pengjun
    Wang, Feng
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S528 - S529
  • [43] Radiochemical Stability of therapeutic radiopharmaceutical of 177Lu-PSMA I&T
    Chandrashekar, R.
    Fagan, J.
    Lim, R.
    Vyas, M.
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 41 - 41
  • [44] Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison
    Rinscheid, Andreas
    Dierks, Alexander
    Kircher, Malte
    Pfob, Christian
    Wengenmair, Hermann
    Wienand, Georgine
    Lapa, Constantin
    Janzen, Tilman
    Bundschuh, Ralph
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [45] Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
    Zaid, Nouran R. R.
    Bastiaannet, Remco
    Hobbs, Rob
    Sgouros, George
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 84 - 90
  • [46] Prostate Cancer Theranostics With 177 Lu-PSMA
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Afshar-Oromieh, Ali
    Kratochwil, Clemens
    Rahbar, Kambiz
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 581 - 590
  • [47] Quality Control Testing of 177Lu
    Lynch, W.
    Mayer, P.
    Murray, L.
    Ladderbush, D.
    Cutler, C.
    Ketring, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S208 - S208
  • [48] Image-Based Bone Marrow Dosimetry in Patients Undergoing [177Lu]Lu-PSMA Radioligand Therapy
    Rumiantcev, M.
    Resch, S.
    Shen, X.
    Liubchenko, G.
    Brendel, M.
    Ziegler, S.
    Boening, G.
    Sheikh, G.
    Delker, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S164 - S164
  • [49] Radiation dosimetric and biodistribution comparison of the PSMA agonists 177Lu-PSMA I&T, 99mTc-Hynic PSMA and 99Tc-PSMA I&T to the 177Lu-RM2 antagonist
    Limouris, G.
    Paphiti, M.
    Zafeirakis, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S459 - S459
  • [50] Preparation of Patient Doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) 177Lu
    Nanabala, Raviteja
    Pillai, Maroor Raghavan Ambikalmajan
    Gopal, Buvaneswari
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 56 (06) : 313 - 322
12345